Analysts Wonder How Affymax Will Fare Against Amgen
By Trista Morrison
Friday, December 9, 2011
Affymax Inc. scored a big win on Wednesday when the FDA's Oncologic Drugs Advisory Committee voted 15-to-1 in favor of peginesatide for dialysis patients with anemia due to chronic kidney disease (CKD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.